Allergan (AGN): Survey Shows Strong Demand for Vralar But No Upgrade- Piper Jaffray

August 30, 2016 7:38 AM EDT
Get Alerts AGN Hot Sheet
Price: $224.86 -0.19%

Rating Summary:
    18 Buy, 13 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 26 | New: 7
Trade AGN Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Piper Jaffray analyst, David Amsellem, reiterated his Neutral rating on shares of Allergen (NYSE: AGN) after conducting a survey of 25 psychiatrists with the goal of gauging perceptions of Allergan’s Vraylar (cariprazine). Notably, the feedback suggests that many psychiatrists perceive at least a modest benefit for Vraylar in reducing negative symptoms associated with schizophrenia. More broadly, the feedback suggests that Vraylar prescription (Rx) volumes will grow significantly.

That said, the 2017E P/E and EV/EBITDA of 14x and 12x, are reflecting expectations for strong growth out of new launches (e.g., Vraylar, Viberzi). Despite the likely success of Vralar, the execution on the pipeline should be the main driver of value creation for the company. This leads the analyst to maintain his Neutral rating along with the price target of $227.

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $236.65 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Piper Jaffray

Add Your Comment